Diagnostic Criteria and Management of Hemosiderosis

Clinical Diagnostic Criteria

The American Society of Hematology recommends that hemosiderosis should be diagnosed when serum ferritin reaches ≥1,000 ng/mL in the setting of chronic transfusion therapy, defined as ≥2 units per month for more than one year or a cumulative transfusion burden of at least 100 mL/kg of packed red blood cells 1, 2
A minimum transfusion burden of 100 mL/kg of packed red blood cells is required before considering hemosiderosis, as cardiac abnormalities do not develop until after >100 units, and liver iron accumulation occurs after >24 units 1, 3
Sustained transfusion requirement of ≥2 units per month for >1 year indicates clinically significant risk for iron overload 1, 2, 4, 5
Serum ferritin consistently >1,000 ng/mL is the primary diagnostic threshold for hemosiderosis requiring intervention 1, 2, 4, 5, 6
Transferrin saturation should be measured alongside ferritin for comprehensive iron status assessment, though specific thresholds are less well-defined than ferritin 6

Iron studies should be assessed at diagnosis of the underlying transfusion-dependent condition and at regular intervals thereafter 6
Every 3 months minimum for all transfusion-dependent patients to track ferritin trends and guide management decisions 1, 2, 4, 5, 6
Monthly monitoring is recommended during initiation or dose increases of iron chelation therapy or in patients with rapidly rising ferritin levels 6
After intravenous iron administration, wait at least 2 weeks before measuring iron parameters for accurate assessment 6

Untreated iron overload causes increased morbidity and mortality from cardiac, hepatic, and endocrine complications 1, 2, 4, 5

Iron chelation should be initiated when ferritin reaches 1,000 ng/mL in transfusion-dependent patients, as this threshold balances prevention of organ damage against treatment burden 1, 2, 4, 5, 3
Patients requiring ≥2 units/month sustained for >1 year should begin chelation even if ferritin has not yet reached 1,000 ng/mL 1, 2, 4, 5
Maintain ferritin between 50-100 μg/L during maintenance therapy to indicate adequate iron depletion without causing iron deficiency 6, 8

In CKD patients on dialysis, iron accumulation occurs primarily in reticuloendothelial cells rather than parenchymal cells, resulting in a different pattern of toxicity than primary hemochromatosis 7
Anemia (hemoglobin <9 g/dL), not elevated ferritin alone, is the primary risk factor for bacteremia in dialysis patients 7
Initiate chelation even with moderate iron overload in transplant candidates, as ferritin >1,000 ng/mL at transplant is associated with higher mortality and increased hepatic complications 3
Low-risk MDS patients (IPSS low or intermediate-I, WHO classifications RA, RARS, 5q-) with life expectancy ≥1 year benefit most from iron overload treatment 1, 2, 4, 5